Identification of GPD1L as a Potential Prognosis Biomarker and Associated with Immune Infiltrates in Lung Adenocarcinoma

Table 1

The association between GPD1L expression and clinicopathological features.

Characteristic	Low expression of GPD1L	High expression of GPD1L
	267	268
Gender, (%)			0.280
Female	136 (25.4%)	150 (28%)
Male	131 (24.5%)	118 (22.1%)
Age, (%)			1.000
< =65	128 (24.8%)	127 (24.6%)
>65	130 (25.2%)	131 (25.4%)
Pathologic stage, (%)			0.004
Stage I	128 (24.3%)	166 (31.5%)
Stage II	72 (13.7%)	51 (9.7%)
Stage III	52 (9.9%)	32 (6.1%)
Stage IV	12 (2.3%)	14 (2.7%)
T stage, (%)			0.692
T1	81 (15.2%)	94 (17.7%)
T2	150 (28.2%)	139 (26.1%)
T3	25 (4.7%)	24 (4.5%)
T4	10 (1.9%)	9 (1.7%)
N stage, (%)			0.002
N0	159 (30.6%)	189 (36.4%)
N1	60 (11.6%)	35 (6.7%)
N2	44 (8.5%)	30 (5.8%)
N3	2 (0.4%)	0 (0%)
M stage, (%)			0.893
M0	186 (48.2%)	175 (45.3%)
M1	12 (3.1%)	13 (3.4%)
Age, median (IQR)	66 (58, 72)	66 (60, 73)	0.372